Induction of oxidative stress by bisphenol A and its pleiotropic effects
Place used needles in an FDA-approved sharps container immediately after use
In the STEP-1 trial published in The New England Journal of Medicine in 2021, once-weekly subcutaneous semaglutide at 2.4 mg produced a mean placebo-adjusted body weight reduction of 12.4% at 68 weeks in adults with overweight or obesity (Wilding et al., NEJM, 2021)
Even a consistent daily deficit of 500 kcal would theoretically produce around 0.5 kg of fat loss per week a change that may be imperceptible on the scales when overlaid with day-to-day weight variation
In trials, the commonly reported side effects included nausea, diarrhea, vomiting, and constipation, and participants generally described them as mild to moderate
Physical Signs of Compromise In addition to changes in the solution, physical damage to the vial itself can be a warning sign